LBPH240621C35000
- 0.35
- 0.000.00%
Longboard Pharmaceuticals Newsroom
Longboard Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Longboard Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Express News | Longboard Pharmaceuticals Inc : Evercore ISI Raises Target Price to $57 From $44
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $60 price target.
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $57 From $44, Maintains Outperform Rating
Longboard Pharmaceuticals (LBPH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $32 to $60.
Longboard Pharmaceuticals Price Target Raised to $36.00/Share From $30.00 by B. Riley Securities
Longboard Pharmaceuticals Price Target Raised to $36.00/Share From $30.00 by B. Riley Securities
Longboard Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Longboard Pharmaceuticals Is Maintained at Buy by B. Riley Securities
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright analyst Patrick Trucchio maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success r
B. Riley Raises Price Target on Longboard Pharmaceuticals to $36 From $30, Maintains Buy Rating
Longboard Pharmaceuticals (LBPH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $32 to $60.
Citi Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $40
Citi analyst David Hoang maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 35.3% and
Express News | Longboard Pharmaceuticals Inc : B. Riley Raises Target Price to $36 From $30
Wedbush Adjusts Longboard Pharmaceuticals Price Target to $42 From $34, Maintains Outperform Rating
Longboard Pharmaceuticals (LBPH) has an average rating of Buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. Price: 17.74, Change: +0.19, Percent Change: +1.08
Express News | Longboard Pharmaceuticals Inc: Favorable Safety and Tolerability Results Observed
Express News | Longboard Pharmaceuticals Announces Positive Interim Results From the Open-Label Extension (Ole) of the Phase 1B/2a Pacific Study Evaluating Bexicaserin in Participants With Developmental and Epileptic Encephalopathies (Dees)
Veeva Introduces Vault Basics for Biotechs
Delivers industry-leading Vault applications in a turnkey solution with no implementation costs for simple adoptionPLEASANTON, Calif., May 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today an
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard's drug development expertise with Beacon's neurophysiological
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains $60 price target.
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin